Portal de Periódicos da CAPES

Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach

2023; Elsevier BV; Volume: 18; Issue: 2 Linguagem: Inglês

10.1016/j.jtho.2022.09.229

1556-1380

Leonardo Provenzano, Silvia Damian, Matteo Duca, S. Della Valle, Filippo de Braud,

Pleural and Pulmonary Diseases

The brief report by Kalchiem-Dekel et al. 1 Kalchiem-Dekel O. Falcon C.J. Bestvina C.M. et al. Brief report: chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy. J Tho Oncol. 2022; 17: 1130-1136 Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar interestingly described the occurrence of spontaneous chylous effusions in patients who underwent treatment with multiple tyrosine kinase inhibitors and specific RET inhibitors. In particular, the incidence of this complication raised to 7% (15 of 217) in patients treated with selpercatinib. The authors also accurately reported the diagnostic workup, which confirmed the fatty nature of the effusions. Nevertheless, no therapeutic approaches other than symptomatic drainage were reported; neither dose reduction obtained an improvement of the condition. Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor TherapyJournal of Thoracic OncologyVol. 17Issue 9PreviewSpontaneous chylous effusions are rare; however, they have been observed by independent investigators in patients treated with RET tyrosine kinase inhibitors (TKIs). Full-Text PDF Response to Provenzano et al. and De Carlo et al.Journal of Thoracic OncologyVol. 18Issue 2PreviewWe appreciate the comments from Provenzano et al. and De Carlo et al. regarding our recently published Brief Report.1 The experiences they shared in the management of patients with chylous ascites on selpercatinib are an important contribution to the literature. As Provenzano et al. mentioned, nontraumatic chylous effusions are rare2 and current management strategies are primarily on the basis of data pertaining to traumatic and iatrogenic chylous effusions, which are more prevalent.3 In our cohort, chylous effusions were most prevalent among patients treated with the selective RET inhibitor, selpercatinib; however, they were also observed among patients treated with multikinase inhibitors with anti-RET activity, specifically cabozantinib, lenvatinib, and agerafenib. Full-Text PDF